197 related articles for article (PubMed ID: 23422917)
21. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.
Katayama Y; Azechi T; Miyazaki M; Takata T; Sekine M; Matsui H; Hanaki H; Yahara K; Sasano H; Asakura K; Takaku T; Ochiai T; Komatsu N; Chambers HF
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827421
[TBL] [Abstract][Full Text] [Related]
22. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
[TBL] [Abstract][Full Text] [Related]
24. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
[TBL] [Abstract][Full Text] [Related]
25. Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.
Lai CC; Chen CC; Chuang YC; Tang HJ
Sci Rep; 2017 Jan; 7():41758. PubMed ID: 28139739
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
27. Identification of a Novel Gene Associated with High-Level β-Lactam Resistance in Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strain Mu3 and Methicillin-Resistant S. aureus Strain N315.
Matsuo M; Yamamoto N; Hishinuma T; Hiramatsu K
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455230
[TBL] [Abstract][Full Text] [Related]
28. Ceftaroline-heteroresistant Staphylococcus aureus.
Saravolatz SN; Martin H; Pawlak J; Johnson LB; Saravolatz LD
Antimicrob Agents Chemother; 2014 Jun; 58(6):3133-6. PubMed ID: 24637680
[TBL] [Abstract][Full Text] [Related]
29. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
[TBL] [Abstract][Full Text] [Related]
30. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.
Cafiso V; Bertuccio T; Spina D; Purrello S; Campanile F; Di Pietro C; Purrello M; Stefani S
PLoS One; 2012; 7(1):e29573. PubMed ID: 22253738
[TBL] [Abstract][Full Text] [Related]
31. Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.
Joukhadar C; Pillai S; Wennersten C; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 2010 Feb; 54(2):773-7. PubMed ID: 19933805
[TBL] [Abstract][Full Text] [Related]
32. Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.
Zheng X; Berti AD; McCrone S; Roch M; Rosato AE; Rose WE; Chen B
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158272
[TBL] [Abstract][Full Text] [Related]
33. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
34. Protein Biomarker Discovery for Methicillin-Sensitive, Heterogeneous Vancomycin-Intermediate and Vancomycin-Intermediate
Liu YC; Lu JJ; Lin LC; Lin HC; Chen CJ
J Proteome Res; 2021 Jan; 20(1):164-171. PubMed ID: 33058664
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin.
Boyle-Vavra S; Yin S; Challapalli M; Daum RS
Antimicrob Agents Chemother; 2003 Mar; 47(3):1028-36. PubMed ID: 12604538
[TBL] [Abstract][Full Text] [Related]
36. Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays.
D'Arezzo S; Mazzarelli A; Venditti C; Nisii C; Petrosillo N; De Giuli C; Vulcano A; Paglia MG; Bordi E; Di Caro A; Taglietti F
Microb Drug Resist; 2017 Jun; 23(4):507-515. PubMed ID: 27526275
[TBL] [Abstract][Full Text] [Related]
37. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
[TBL] [Abstract][Full Text] [Related]
38. Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphyloccus aureus.
Bakar NS; Zin NM; Basri DF
Pak J Pharm Sci; 2012 Jul; 25(3):633-8. PubMed ID: 22713953
[TBL] [Abstract][Full Text] [Related]
39. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.
Hagihara M; Wiskirchen DE; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2012 Jan; 56(1):202-7. PubMed ID: 22006007
[TBL] [Abstract][Full Text] [Related]
40. Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.
Roch M; Clair P; Renzoni A; Reverdy ME; Dauwalder O; Bes M; Martra A; Freydière AM; Laurent F; Reix P; Dumitrescu O; Vandenesch F
Antimicrob Agents Chemother; 2014 Sep; 58(9):5306-14. PubMed ID: 24957836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
